ReviewClinical & developmental immunology2011
Cytokines: the future of intranasal vaccine adjuvants.
Review in Clinical & developmental immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 70 citations in OpenAlex.
- Next-generation mucosal vaccines for respiratory viruses: Immunological correlates, platform design and clinical translation.World journal of virology · 2026Review
- Designing a Vaccine for the Monkeypox Virus Using Immunoinformatics and Structural Tools.Advanced biomedical research · 2026Article
- Intranasal Immunization with Nasal Immuno-Inducible Sequence-Fused Antigens Elicits Antigen-Specific Antibody Production.International journal of molecular sciences · 2024Article
- Article
- Recent trends in next generation immunoinformatics harnessed for universal coronavirus vaccine design.Pathogens and global health · 2023Review
- Nano-Encapsulated Antioxidant: Retinoic Acid as a Natural Mucosal Adjuvant for Intranasal Immunization against Chronic Experimental Toxoplasmosis.Tropical medicine and infectious disease · 2023Article
- How Long Will It Take to Launch an EffectiveInfection and drug resistance · 2023Review
- Nano-Encapsulated Melatonin: A Promising Mucosal Adjuvant in Intranasal Immunization against Chronic ExperimentalTropical medicine and infectious disease · 2022Article
- Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy.Journal of translational medicine · 2022Article
- Development of mucosal vaccine delivery: an overview on the mucosal vaccines and their adjuvants.Clinical and experimental vaccine research · 2022Review
- Role of Interleukin-6 in the Antigen-Specific Mucosal Immunoglobulin A Responses Induced by CpG Oligodeoxynucleotide-Loaded Cationic Liposomes.Membranes · 2022Article
- Role of interleukin-6 in antigen-specific mucosal immunoglobulin A induction by cationic liposomes.International immunopharmacology · 2021Article
- Genome based evolutionary lineage of SARS-CoV-2 towards the development of novel chimeric vaccine.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2020Article
- Article
- Advances in Fungal Peptide Vaccines.Journal of fungi (Basel, Switzerland) · 2020Review
- Plant-derived protein bodies as delivery vehicles for recombinant proteins into mammalian cells.Biotechnology and bioengineering · 2020Article
- Epitope Prediction by Novel Immunoinformatics Approach: A State-of-the-art Review.International journal of peptide research and therapeutics · 2020Review
- Novel Candidates for Vaccine Development AgainstVaccines · 2019Review
- Intranasal administration of cationic liposomes enhanced granulocyte-macrophage colony-stimulating factor expression and this expression is dispensable for mucosal adjuvant activity.BMC research notes · 2018Article
- Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl/6 mice.Parasites & vectors · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to its potential as an effective, needle-free route of immunization for use with subunit vaccines, nasal immunization continues to be evaluated as a route of immunization in both research and clinical studies. However, as with other vaccination routes, subunit vaccines often require the addition of adjuvants to induce potent immune responses. Unfortunately, many commonly used experimental vaccine adjuvants, such as cholera toxin and E. coli heat-labile toxin, are too toxic for use in humans. Because new adjuvants are needed, cytokines have been evaluated for their ability to provide effective adjuvant activity when delivered by the nasal route in both animal models and in limited human studies. It is the purpose of this paper to discuss the potential of cytokines as nasal vaccine adjuvants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.